Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Decrease in Short Interest

Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 8,090,000 shares, a drop of 16.2% from the February 13th total of 9,650,000 shares. Currently, 6.5% of the company’s stock are short sold. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is presently 7.0 days.

Insider Buying and Selling at Lyell Immunopharma

In other Lyell Immunopharma news, Director Richard Klausner purchased 158,000 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was bought at an average cost of $0.60 per share, with a total value of $94,800.00. Following the acquisition, the director now directly owns 843,365 shares of the company’s stock, valued at approximately $506,019. This represents a 23.05 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Charles W. Newton purchased 200,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was bought at an average price of $0.56 per share, for a total transaction of $112,000.00. Following the completion of the purchase, the chief financial officer now directly owns 200,000 shares of the company’s stock, valued at $112,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 533,000 shares of company stock valued at $313,550 in the last quarter. Corporate insiders own 25.10% of the company’s stock.

Institutional Trading of Lyell Immunopharma

Several large investors have recently modified their holdings of LYEL. Centiva Capital LP acquired a new position in Lyell Immunopharma in the 3rd quarter valued at $31,000. Graham Capital Management L.P. purchased a new position in Lyell Immunopharma in the fourth quarter valued at about $33,000. RPO LLC purchased a new position in Lyell Immunopharma in the 4th quarter worth approximately $42,000. Intech Investment Management LLC purchased a new stake in shares of Lyell Immunopharma during the third quarter valued at approximately $52,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Lyell Immunopharma in the 3rd quarter worth $52,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Trading Up 20.3 %

Shares of NASDAQ:LYEL traded up $0.10 during midday trading on Wednesday, hitting $0.58. The stock had a trading volume of 2,315,737 shares, compared to its average volume of 1,044,535. The stock has a 50 day moving average price of $0.62 and a two-hundred day moving average price of $0.89. Lyell Immunopharma has a 1 year low of $0.48 and a 1 year high of $3.15. The company has a market capitalization of $171.76 million, a PE ratio of -0.74 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, equities analysts expect that Lyell Immunopharma will post -0.78 EPS for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.